Alexandra Calmy

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients
    A Calmy
    Division of Infectious Diseases, HIV Unit, Department of Internal Medicine, University Hospitals of Geneva, Switzerland
    HIV Med 13:207-18. 2012
  2. ncbi Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon
    Jules B Tchatchueng Mbougua
    Institut de Recherche pour le Developpement, University Montpellier 1, UMR 145, Montpellier, France
    BMC Public Health 10:105. 2010
  3. ncbi When to start antiretroviral therapy in resource-limited settings: a human rights analysis
    Nathan Ford
    Medecins Sans Frontieres, Cape Town, South Africa
    BMC Int Health Hum Rights 10:6. 2010
  4. ncbi Reduction of missed appointments at an urban primary care clinic: a randomised controlled study
    Noelle Junod Perron
    Division of Primary Care, Department of Community Medicine and Primary Care, Geneva University Hospitals, Geneva, Switzerland
    BMC Fam Pract 11:79. 2010
  5. ncbi A new era of antiretroviral drug toxicity
    Alexandra Calmy
    Geneva University Hospital, HIV Unit, Geneva, Switzerland
    Antivir Ther 14:165-79. 2009
  6. ncbi Safety and efficacy of once-daily nevirapine dosing: a multicohort study
    Alexandra Calmy
    Division of Infectious Disease HIV unit, University Hospital Geneva, Geneva, Switzerland
    Antivir Ther 14:931-8. 2009
  7. ncbi HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, 15 rue Micheli Du Crest, Geneva 1205, Switzerland
    AIDS 23:929-39. 2009
  8. ncbi HIV viral load monitoring in resource-limited regions: optional or necessary?
    Alexandra Calmy
    Medecins Sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland
    Clin Infect Dis 44:128-34. 2007
  9. ncbi Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections
    Juan Ambrosioni
    Laboratory of Virology, Department of Genetics and Laboratory Medicine, University Hospital, Geneva, Switzerland
    AIDS 26:2079-86. 2012
  10. ncbi Health perceptions of African HIV-infected patients and their physicians
    Melissa I Dominicé Dao
    Geneva University Hospitals, Community Medicine and Primary Care Department, Geneva, Switzerland
    Patient Educ Couns 80:185-90. 2010

Collaborators

Detail Information

Publications19

  1. ncbi Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients
    A Calmy
    Division of Infectious Diseases, HIV Unit, Department of Internal Medicine, University Hospitals of Geneva, Switzerland
    HIV Med 13:207-18. 2012
    ..We aimed to determine the antibody responses and effect on viral load of the AS03-adjuvanted pandemic H1N1 vaccine in HIV-infected patients...
  2. ncbi Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon
    Jules B Tchatchueng Mbougua
    Institut de Recherche pour le Developpement, University Montpellier 1, UMR 145, Montpellier, France
    BMC Public Health 10:105. 2010
    ....
  3. ncbi When to start antiretroviral therapy in resource-limited settings: a human rights analysis
    Nathan Ford
    Medecins Sans Frontieres, Cape Town, South Africa
    BMC Int Health Hum Rights 10:6. 2010
    ....
  4. ncbi Reduction of missed appointments at an urban primary care clinic: a randomised controlled study
    Noelle Junod Perron
    Division of Primary Care, Department of Community Medicine and Primary Care, Geneva University Hospitals, Geneva, Switzerland
    BMC Fam Pract 11:79. 2010
    ..The aim of this study was to test the effectiveness of a sequential intervention reminding patients of their upcoming appointment and to identify the profile of patients missing their appointments...
  5. ncbi A new era of antiretroviral drug toxicity
    Alexandra Calmy
    Geneva University Hospital, HIV Unit, Geneva, Switzerland
    Antivir Ther 14:165-79. 2009
    ..We review life-threatening adverse events, adverse events of new investigational or recently marketed drugs, adverse events with a genetic component and tissue-specific adverse events of fat, heart, bone, kidney and liver...
  6. ncbi Safety and efficacy of once-daily nevirapine dosing: a multicohort study
    Alexandra Calmy
    Division of Infectious Disease HIV unit, University Hospital Geneva, Geneva, Switzerland
    Antivir Ther 14:931-8. 2009
    ..Nevirapine (NVP) is often prescribed once daily in clinical practice in combination with a once daily nucleoside backbone. We investigated the relationship of NVP dosing with safety and efficacy...
  7. ncbi HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, 15 rue Micheli Du Crest, Geneva 1205, Switzerland
    AIDS 23:929-39. 2009
    ..We investigated whether HIV replication modified the levels of these proteins in a combination antiretroviral therapy (cART) interruption trial...
  8. ncbi HIV viral load monitoring in resource-limited regions: optional or necessary?
    Alexandra Calmy
    Medecins Sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland
    Clin Infect Dis 44:128-34. 2007
    ..Rather than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes affordable, simple, and easy to use in resource-limited settings...
  9. ncbi Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections
    Juan Ambrosioni
    Laboratory of Virology, Department of Genetics and Laboratory Medicine, University Hospital, Geneva, Switzerland
    AIDS 26:2079-86. 2012
    ..To evaluate HIV-1 transmission trends and the impact of highly active antiretroviral therapy (HAART) on newly diagnosed HIV infections in Geneva, Switzerland...
  10. ncbi Health perceptions of African HIV-infected patients and their physicians
    Melissa I Dominicé Dao
    Geneva University Hospitals, Community Medicine and Primary Care Department, Geneva, Switzerland
    Patient Educ Couns 80:185-90. 2010
    ....
  11. ncbi Preferred antiretroviral drugs for the next decade of scale up
    Isabelle Andrieux-Meyer
    Medecins Sans Frontieres, Geneva, Switzerland
    J Int AIDS Soc 15:17986. 2012
    ..This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings...
  12. ncbi HIV treatment for prevention
    Juan Ambrosioni
    HIV Unit, Department of Infectious Diseases, University of Geneva Hospitals, Geneva, Switzerland
    J Int AIDS Soc 14:28. 2011
    ..This will lead to a decrease in HIV transmission while "test-and-treat" is fully explored in prospective clinical trials...
  13. ncbi Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
    Nathan Ford
    Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa
    AIDS 25:2301-4. 2011
    ..85 (95% CI 0.61-1.20). One neural tube defect was observed (myelomeningocele), giving an incidence of 0.07% (95% CI 0.002-0.39)...
  14. ncbi Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
    Janice Soo Fern Lee
    Medecins Sans Frontieres, Geneva University Hospital, Geneva, Switzerland
    HIV AIDS (Auckl) 4:5-15. 2012
    ..Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged...
  15. ncbi Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy
    Alexandra Calmy
    Division of aInfectious Diseases, , Geneva, Switzerland
    AIDS 17:770-2. 2003
  16. ncbi The first decade of antiretroviral therapy in Africa
    Nathan Ford
    Medecins Sans Frontieres, Geneva, Switzerland
    Global Health 7:33. 2011
    ....
  17. ncbi Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
    Nathan Ford
    Medecins Sans Frontieres, Geneva, Switzerland
    HIV AIDS (Auckl) 3:35-44. 2011
    ..These characteristics make rilpivirine an attractive drug for resource-limited settings. Future research should assess the potential to improve robustness and assess the clinical significance of interaction with antituberculosis drugs...
  18. ncbi Driving a decade of change: HIV/AIDS, patents and access to medicines for all
    Ellen t Hoen
    Medicines Patent Pool Initiative, UNITAID Secretariat, Geneva, Switzerland
    J Int AIDS Soc 14:15. 2011
    ..Governments must live up to their obligations to protect access to medicines as a fundamental component of the human right to health...
  19. ncbi Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia
    Tristan Ferry
    Geneva University Hospital, Geneva, Switzerland
    Clin Infect Dis 50:115-8. 2010
    ..Sixteen patients had circulating DNA, with no apparent clinical impact. Erythrovirus-associated anemia is an extremely rare event in HIV-infected patients...